Amalgamated Financial’s Editas Medicine EDIT Stock Holding History

Amalgamated Financial’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$212K	Buy	+11,152	New	+$207K	﹤0.01%	1875

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Amalgamated Financial's EDIT Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Editas Medicine (EDIT) in Q1 2022: 11,152 shares worth $212K. The stake represents ﹤0.01% of the portfolio and ranks #1875 among its holdings.

257 funds tracked by Wall St. Rank hold EDIT as of Q1 2022.

Amalgamated Financial held 11,152 shares of Editas Medicine worth $212K as of Q1 2022.
Editas Medicine was a new Amalgamated Financial position in Q1 2022.
Editas Medicine made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1875 holding.
257 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.